The Effect of Imatinib on Cytomegalovirus Reactivation in Hematopoietic Cell Transplantation | Zendy

Giovanna Travi | Zendy; Steven A. Pergam | Zendy; Hu Xie | Zendy; Paul A. Carpenter | Zendy; HansPeter Kiem | Zendy; Lawrence Corey | Zendy; Michael Boeckh | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The Effect of Imatinib on Cytomegalovirus Reactivation in Hematopoietic Cell Transplantation

Author(s) -

Giovanna Travi,

Steven A. Pergam,

Hu Xie,

Paul A. Carpenter,

HansPeter Kiem,

Lawrence Corey,

Michael Boeckh

Publication year - 2009

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/648120

Subject(s) - medicine , imatinib , hematopoietic cell , tyrosine kinase , tyrosine kinase inhibitor , transplantation , cytomegalovirus , hematopoietic stem cell transplantation , immunology , cancer research , virology , haematopoiesis , oncology , virus , stem cell , viral disease , herpesviridae , biology , cancer , receptor , myeloid leukemia , genetics

In vitro studies have shown possible antiviral effects of tyrosine kinase inhibitors. In a retrospective study, we show that use of the tyrosine kinase inhibitor imatinib does not appear to reduce cytomegalovirus reactivation during the first 100 days after transplantation in a cohort of hematopoietic cell transplant recipients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research